§ 21-2B-01. Definitions
West's Annotated Code of MarylandHealth--GeneralEffective: October 1, 2017
Effective: October 1, 2017
MD Code, Health - General, § 21-2B-01
§ 21-2B-01. Definitions
(c) “Eligible patient” means an individual who:
(d) “Health occupations board” means a board established under the Health Occupations Article that issues licenses to practice a health occupation in the State.
(e) “Informed consent” means a written document prepared using the informed consent form developed by the Office of the Attorney General in accordance with § 21-2B-02(d)(1) of this subtitle that:
(v) Describes the best and worst potential outcomes of using the investigational drug, biological product, or device with a realistic description of the most likely outcome, including the possibility that new, unanticipated, different, or worse symptoms might result and that death could be hastened by the proposed treatment, based on the treating physician's knowledge of the proposed treatment in conjunction with an awareness of the patient's condition;
(vii) Makes clear that the patient's eligibility for hospice care may be withdrawn if the patient begins curative treatment with the investigational drug, biological product, or device and that hospice care may be reinstated if this treatment ends and the patient meets hospice eligibility requirements; and
(f) “Investigational drug, biological product, or device” means a drug, biological product, or device that:
Credits
Added by Acts 2017, c. 771, § 1, eff. Oct. 1, 2017.
MD Code, Health - General, § 21-2B-01, MD HEALTH GEN § 21-2B-01
Current through legislation effective through April 9, 2023, from the 2024 Regular Session of the General Assembly. Some statute sections may be more current, see credits for details.
End of Document |